ZOE Stock Overview
Engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Zoetis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$154.46 |
| 52 Week High | US$159.20 |
| 52 Week Low | US$154.46 |
| Beta | 0.76 |
| 1 Month Change | 0% |
| 3 Month Change | 0.97% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 10.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZOE | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | 0% | -7.3% | 0.6% |
| 1Y | n/a | -3.3% | 12.9% |
Return vs Industry: Insufficient data to determine how ZOE performed against the BG Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ZOE performed against the BG Market.
Price Volatility
| ZOE volatility | |
|---|---|
| ZOE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in BG Market | 8.2% |
| 10% least volatile stocks in BG Market | 2.4% |
Stable Share Price: ZOE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ZOE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 13,800 | Kristin Peck | www.zoetis.com |
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives.
Zoetis Inc. Fundamentals Summary
| ZOE fundamental statistics | |
|---|---|
| Market cap | €74.34b |
| Earnings (TTM) | €1.92b |
| Revenue (TTM) | €7.34b |
38.7x
P/E Ratio10.1x
P/S RatioIs ZOE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZOE income statement (TTM) | |
|---|---|
| Revenue | US$8.08b |
| Cost of Revenue | US$2.45b |
| Gross Profit | US$5.63b |
| Other Expenses | US$3.52b |
| Earnings | US$2.11b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
May 04, 2023
| Earnings per share (EPS) | 4.57 |
| Gross Margin | 69.73% |
| Net Profit Margin | 26.16% |
| Debt/Equity Ratio | 180.3% |
How did ZOE perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield29%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/02 19:41 |
| End of Day Share Price | 2023/02/03 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zoetis Inc. is covered by 43 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Balaji Prasad | Barclays |